Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda #productrecall #oncology #cancerresearch
Saturday, March 14, 2026, 12:23 am / permalink 20738 / 3 stories in 2 days
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (16 hrs)
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)
Vitamin D trial shows reduced long‑COVID risk but no severity benefit (19 hrs)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.